Full-Time

Associate Director

Oncology Insights Lead

Posted on 5/9/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$167.2k - $250.8k/yr

+ Bonus + Equity Grants

San Francisco, CA, USA + 2 more

More locations: Philadelphia, PA, USA | San Diego, CA, USA

In Person

Category
Business & Strategy (2)
,
Required Skills
Power BI
Python
SAS
R
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in a quantitative, scientific, or business discipline.
  • 6+ years of progressive experience in commercial analytics, insights, strategy, or consulting within pharma/biotech; prior consulting experience preferred.
  • Experience supporting specialty or complex Therapeutic Areas preferred.
  • Strong experience with secondary data analytics, including claims, EHR/EMR, specialty pharmacy, prescriber‑level, and real-world data.
  • Demonstrated ability to leverage predictive analytics to inform commercial and strategic decisions.
  • Proficiency with analytics and visualization tools (Power BI, Excel).
  • Exposure to Python, R, or SAS is a plus.
  • Exceptional stakeholder management and influencing skills, particularly with senior leaders and cross‑functional partners.
  • Strong storytelling and communication abilities.
  • Consulting‑style problem‑solving skills, with comfort navigating ambiguity and structuring work around decisions.
  • Strong project and initiative management capabilities.
  • Collaborative, adaptable mindset, effective in fast‑paced, evolving organizations.
  • High intellectual curiosity and continuous‑learning orientation, especially in analytics, data, and commercial best practices.
  • Exposure to advanced analytics or AI‑enabled insights is a plus, but not required.
Responsibilities
  • Define and advance the analytics vision and operating approach for the Therapeutic Area to strengthen data‑driven decision‑making across brands and the portfolio.
  • Serve as a senior analytics and insights advisor to leadership, influencing strategies, priorities, and tactics through objective, data‑backed recommendations.
  • Shape near‑and mid‑term priorities in partnership with Marketing, Sales, and cross‑functional stakeholders, grounded in patient and provider experiences, outcomes,dataand evolving market dynamics.
  • Represent analytics in planning cycles, business reviews, and leadership forums, contributing to enterprise‑level discussions and decisions.
  • Lead the integration and triangulation of secondary data sources to develop a unified view of patient journeys, treatment patterns, and competitive dynamics.
  • Apply predictive analytics and identify leading vs lagging indicators to inform forecasting, opportunity assessment, targeting, and risk evaluation.
  • Partner with cross‑functional teams to develop scalable analytical frameworks, metrics, and decision‑support tools that enable consistent, repeatable decision‑making.
  • Ensure delivery of high-quality dashboards and executive‑level reporting, providing clear, actionable visibility into brand and portfolio performance.
  • Translate complex analyses into compelling, executive‑ready narratives that inform strategic choices and resource allocation.
  • Lead design and execution of qualitative and quantitative primary market research to address key strategic and tactical business questions.
  • Synthesize insights from primary research and secondary data to represent a holistic “voice of the customer”.
  • Facilitate insight‑sharing with brand and matrix teams to deepen understanding of product perceptions, usage drivers, market dynamics, and competitive context.
  • Build strong, trusted partnerships across functions including Medical, Market Access, Sales Operations, Brand, Data Strategy, and IT.
  • Drive alignment on Therapeutic Area and cross‑portfolio analytics priorities.
  • Act as a connective bridge across teams, translating insights into coordinated action and execution.
  • Influence without authority in a matrixed environment, balancing multiple perspectives while maintaining focus on enterprise and patient outcomes.
  • Continuously evaluate emerging data assets, analytical techniques, and technologies to ensure analytics capabilities evolve with the business.
  • Identify opportunities to streamline, standardize, and improve analytics processes to increase speed, quality, and impact.
  • Experiment thoughtfully with new approaches, incorporating learnings from both successes and failures to strengthen analytics over time.
Desired Qualifications
  • Advanced degree (MBA, MS, PhD) strongly preferred.
  • Exposure to AI-enabled insights or advanced analytics is a plus.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • Epidiolex generated $1.1B in 2025 sales, up 9% YoY, with patents protected to late 2030s.
  • Q1 2026 revenue hit $1.1B, up 19% YoY, prompting Raymond James target raise to $239 on May 7.
  • Chimerix acquisition adds dordaviprone for H3 K27M-mutant glioma, PDUFA August 18, 2025.

What critics are saying

  • Generic competition erodes Xywav revenue as it replaces Xyrem, decelerating growth to 5.5% annually.
  • Dordaviprone fails FDA approval on August 18, 2025 PDUFA, wasting $935M Chimerix acquisition.
  • $850M exchangeable notes due 2030 dilute equity at $153.05 exchange price amid EPS decline.

What makes Jazz Pharmaceuticals unique

  • Jazz Pharmaceuticals focuses on neuroscience and oncology for rare diseases with limited treatments.
  • Xywav offers 92% less sodium than Xyrem, approved July 21, 2020, for narcolepsy in patients aged 7+.
  • Epidiolex, acquired via $7.2B GW Pharma deal in 2021, treats Lennox-Gastaut and Dravet syndromes.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Jazz Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Intellectia.AI
Mar 4th, 2026
Day One Biopharmaceuticals shares surge 28% on takeover rumours from Ipsen and Jazz

Day One Biopharmaceuticals shares surged 28% amid acquisition rumours, with Jazz Pharmaceuticals and Ipsen cited as potential acquirers. Eight out of nine analysts rate the stock as "buy" or higher, with an average price target of $22.75 representing over 75% upside. The company reported Q4 2025 revenue of $52.8 million for its drug Ojemda, an 83% year-over-year increase. Full-year 2025 net product revenue reached $155.4 million, up 172%. Despite a net loss of $107.3 million in 2025, Day One projects 2026 US revenue between $225 million and $250 million. The biopharmaceutical firm ended 2025 with $441.1 million in cash and no debt. Retail sentiment on Stocktwits remained "extremely bullish" as speculation about a potential merger intensified.

Yahoo Finance
Feb 28th, 2026
Jazz Pharmaceuticals' CBD drug Epidiolex hits $1B in sales — time to buy the stock?

Jazz Pharmaceuticals' cannabidiol therapy Epidiolex has surpassed $1 billion in annual product sales, achieving blockbuster status. The drug, which treats seizures associated with rare epilepsy syndromes, generated $1.1 billion in 2025, representing approximately a quarter of Jazz's total revenues and marking 9% year-over-year growth. Jazz acquired Epidiolex through its $7.2 billion purchase of GW Pharmaceuticals in 2021. The company has resolved nearly all outstanding generic litigation, extending patent protection into the late 2030s and reducing competitive threats. Management sees significant growth potential in adult patients, particularly within long-term care settings. The company is investing in diagnostic tools and patient-support programmes to expand adoption beyond paediatric use. Jazz's portfolio also includes successful neuroscience and oncology products.

Yahoo Finance
Feb 25th, 2026
Jazz Pharmaceuticals shares jump 13.5% on strong Q4 results with $1.2B revenue

Jazz Pharmaceuticals shares rose 13.5% after reporting fourth-quarter 2025 revenue of $1.2 billion, up 10.1% year-on-year and exceeding analyst estimates. Adjusted earnings of $6.64 per share also beat expectations. The company's operating margin expanded to 21.2% from 17.5% in the prior year, demonstrating improved operational efficiency. However, full-year revenue guidance fell short of consensus estimates. Investors appeared to focus on the strong quarterly performance despite the mixed outlook. The shares reached a new 52-week high of $196.34, bringing year-to-date gains to 13.4%. The stock has experienced significant volatility, with 12 moves greater than 5% over the past year.

Jazz Pharmaceuticals
Jun 23rd, 2025
Jazz Pharmaceuticals and Azur Pharma Combine to Create Jazz Pharmaceuticals plc | Jazz Pharmaceuticals plc

DUBLIN , Jan. 18, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of the business combination of Jazz Pharmaceuticals, Inc. and Azur Pharma plc .  The two companies have combined to create Jazz Pharmaceuticals plc , a specialty biopharmaceutical company

CityBiz
Mar 5th, 2025
Jazz Pharmaceuticals Acquires Chimerix for $935M

Jazz Pharmaceuticals is set to acquire Chimerix for $935 million, paying $8.55 per share in cash. The acquisition, expected to close in Q2 2025, will add Chimerix's lead asset, dordaviprone, to Jazz's portfolio. Dordaviprone is a treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor. The FDA has accepted its NDA for accelerated approval, with a PDUFA date of August 18, 2025. Jazz plans to fund the deal through existing cash and investments.